192 related articles for article (PubMed ID: 32424526)
1. Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting.
Bokemeyer B; Ghiani M; Fuchs A; Deiters B; Hardtstock F; Brandes A; Knop J; Orzechowski HD; Wilke T
Int J Colorectal Dis; 2020 Aug; 35(8):1587-1598. PubMed ID: 32424526
[TBL] [Abstract][Full Text] [Related]
2. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
[TBL] [Abstract][Full Text] [Related]
3. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
Jung YS; Han M; Park S; Cheon JH
Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
[TBL] [Abstract][Full Text] [Related]
4. Change in systemic steroid use and surgery rate in patients with inflammatory bowel disease: a Japanese real-world database analysis.
Hirayama D; Hyodo S; Morita K; Nakase H
J Gastroenterol; 2024 May; 59(5):389-401. PubMed ID: 38492011
[TBL] [Abstract][Full Text] [Related]
5. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
6. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs.
Dignass A; Waller J; Cappelleri JC; Modesto I; Kisser A; Dietz L; DiBonaventura M; Wood R; May M; Libutzki B; Bargo D
J Med Econ; 2020 Apr; 23(4):415-427. PubMed ID: 31858853
[No Abstract] [Full Text] [Related]
7. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
[TBL] [Abstract][Full Text] [Related]
8. Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies.
Cai Q; Ding Z; Fu AZ; Patel AA
BMC Gastroenterol; 2022 Dec; 22(1):545. PubMed ID: 36581802
[TBL] [Abstract][Full Text] [Related]
9. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil.
Sassaki LY; Miszputen SJ; Kaiser Junior RL; Catapani WR; Bafutto M; Scotton AS; Zaltman C; Baima JP; Ramos HS; Faria MAG; Gonçalves CD; Guimaraes IM; Flores C; Amarante HMBS; Nones RB; Parente JML; Lima MM; Chebli JM; Ferrari MLA; Campos JF; Sanna MGP; Ramos O; Parra RS; da Rocha JJR; Feres O; Feitosa MR; Caratin RF; Senra JT; Santana GO
World J Gastroenterol; 2021 Jun; 27(23):3396-3412. PubMed ID: 34163120
[TBL] [Abstract][Full Text] [Related]
10. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study).
Abraham B; Eksteen B; Nedd K; Kale H; Patel D; Stephens J; Shelbaya A; Chambers R; Soonasra A
Adv Ther; 2022 May; 39(5):2109-2127. PubMed ID: 35296993
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
[TBL] [Abstract][Full Text] [Related]
13. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
[TBL] [Abstract][Full Text] [Related]
14. Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort Study.
Khoudari G; Mansoor E; Click B; Alkhayyat M; Saleh MA; Sinh P; Katz J; Cooper GS; Regueiro M
Clin Gastroenterol Hepatol; 2022 May; 20(5):e974-e983. PubMed ID: 33065311
[TBL] [Abstract][Full Text] [Related]
15. Early Initiation of Biologics and Disease Outcomes in Adults and Children With Inflammatory Bowel Diseases: Results From the Epidemiology Group of the Nationwide Israeli Inflammatory Bowel Disease Research Nucleus Cohort.
Lujan R; Buchuk R; Focht G; Yogev D; Greenfeld S; Ben-Tov A; Weisband YL; Lederman N; Matz E; Ben Horin S; Dotan I; Nevo D; Turner D
Gastroenterology; 2024 May; 166(5):815-825.e22. PubMed ID: 38331205
[TBL] [Abstract][Full Text] [Related]
16. The cost burden of Crohn's disease and ulcerative colitis depending on biologic treatment status - a Danish register-based study.
Alulis S; Vadstrup K; Olsen J; Jørgensen TR; Qvist N; Munkholm P; Borsi A
BMC Health Serv Res; 2021 Aug; 21(1):836. PubMed ID: 34407821
[TBL] [Abstract][Full Text] [Related]
17. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany.
Wilke T; Groth A; Long GH; Tatro AR; Sun D
Clin Ther; 2020 Jan; 42(1):130-143.e3. PubMed ID: 31883702
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
[No Abstract] [Full Text] [Related]
19. Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil.
Zaltman C; Parra RS; Sassaki LY; Santana GO; Ferrari MLA; Miszputen SJ; Amarante HMBS; Kaiser Junior RL; Flores C; Catapani WR; Parente JML; Bafutto M; Ramos O; Gonçalves CD; Guimaraes IM; da Rocha JJR; Feitosa MR; Feres O; Saad-Hossne R; Penna FGC; Cunha PFS; Gomes TN; Nones RB; Faria MAG; Parente MPPD; Scotton AS; Caratin RF; Senra J; Chebli JM
World J Gastroenterol; 2021 Jan; 27(2):208-223. PubMed ID: 33510560
[TBL] [Abstract][Full Text] [Related]
20. Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States.
Long MD; Smith TW; Dibonaventura M; Gruben D; Bargo D; Salese L; Quirk D
Inflamm Bowel Dis; 2020 May; 26(6):941-948. PubMed ID: 31560046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]